According to Zacks, “VectivBio Holding AG is a clinical stage biopharmaceutical company. It is focused on the discovery, development and commercialization of treatments for severe rare conditions for which there is a significant unmet medical need. VectivBio Holding AG is based in BASEL, Switzerland. “
Shares of VECT stock traded up $0.48 during midday trading on Wednesday, reaching $6.50. 305 shares of the company were exchanged, compared to its average volume of 16,705. VectivBio has a 12 month low of $2.74 and a 12 month high of $16.75. The company’s 50 day moving average price is $5.13 and its two-hundred day moving average price is $4.90.
VectivBio Company Profile (Get Rating)
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for rare conditions. It develops Apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as for SBS-IF in patients with colon-in-continuity anatomy.
- Get a free copy of the StockNews.com research report on VectivBio (VECT)
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Dynatrace: Fundamentals are Positive While Being Punished
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
- Now’s The Time To Buy Disney (NYSE: DIS)
- 3 Small Caps With Big Return Potential
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VectivBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VectivBio and related companies with MarketBeat.com's FREE daily email newsletter.